Evaluation of DAO-deficiency in patients with migraine. (MigraDAO trial)
Carmen Vidal1, Feliu Titus2 y Rafael Guayta-Escolies3
1 Professor of Nutrition and Bromatology at University of Barcelona, Barcelona (Spain)
2 Member of honour in the Spanish Society of Neorology, Madrid (Spain) and Scientific assessor in the Spanish Association of Patients with Headache (AEPAC), Valencia (Spain)
3 Assessor in the Department of Clinical projects at the Pharmacists Association of Barcelona (Spain)
Presented in the International Awareness Day for migraine at the Spanish Parliament, coinciding with the Spanish presidency of the European Union; 24th may 2010.
To determine the proportion of patients diagnosed with migraine that present DAO-deficiency regarding the observed deficit in non-migrainous population.
Migrainous patients present lower DAO concentrations than healthy subjects. Therefore, this deficiency may be the cause of histamine intolerance and represents a physiopathological factor of the studied neurological entity. That being the case, an etiologic treatment approach could be hypothesized based on the administration of DAO in patients with this deficiency.
Design of the trial:
A descriptive observational cross-sectional prospective study with a control group without masking or randomisation.
The target population are volunteer subjects suffering migraine, members of the Spanish Association of Patients with Headache that meet the diagnostic criteria accepted by the International Headache Society (IHS). The healthy controls are chosen among volunteers of their microsocial environment.